Insider · CIK 0002049757
Ken Herrmann
Files at AKTS (Aktis Oncology, Inc.). First filing Jul 20, 2026, latest Jul 21, 2026.
In brief
Ken Herrmann files SEC Form 4 as director at AKTS (Aktis Oncology, Inc.). Since Jul 20, 2026, Ken Herrmann has reported 0 open-market buys worth $0 and 2 open-market sells worth $197k, the latest filed on Jul 21, 2026.
A track record needs three past buys with six months of prices behind them; Ken Herrmann has 0, so none is measured yet.
The newest scored trade: sold $119k of AKTS on Jul 20, 2026, filed Jul 21, 2026, scored 45 (moderate). In the last 12 months: 0 buys worth $0 and 2 sells worth $197k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKTS: Aktis Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | Aktis Oncology, Inc. | $119k 4,856 shares | -100% | +58% from low-26% from high | |
| 43Moderate | Aktis Oncology, Inc. | $77k 3,065 shares | -100% | +64% from low-23% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 20, 2026 | AKTS AKTIS ONCOLOGY, INC. | 4,856 0.01% of outstanding | $119k | Jul 20, 2026 | $77k |
| Jul 17, 2026 | AKTS AKTIS ONCOLOGY, INC. | 3,065 0.01% of outstanding | $77k | Jul 17, 2026 | none |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Common Stock | +3,506 | $0.08 | $280 | 3,506 | Jul 21, 2026 |
| Jul 20, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Common Stock | +1,350 | $1.91 | $2,579 | 4,856 | Jul 21, 2026 |
| Jul 20, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -3,506 | $24.56 | $86k | 1,350 | Jul 21, 2026 |
| Jul 20, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -1,350 | $24.56 | $33k | 0 | Jul 21, 2026 |
| Jul 20, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -3,506 | $0.00 | $0 | 0 | Jul 21, 2026 |
| Jul 20, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -1,350 | $0.00 | $0 | 18,364 | Jul 21, 2026 |
| Jul 17, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Common Stock | +3,065 | $0.08 | $245 | 3,065 | Jul 20, 2026 |
| Jul 17, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -3,065 | $25.21 | $77k | 0 | Jul 20, 2026 |
| Jul 17, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -3,065 | $0.00 | $0 | 3,506 | Jul 20, 2026 |
Questions about Ken Herrmann
Answered from the filings on this page, as of the latest one.
Is Ken Herrmann buying or selling?
In the last 12 months Ken Herrmann reported 0 open-market buys worth $0 and 2 open-market sells worth $197k on SEC Form 4; the latest was sold $119k of AKTS on Jul 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Ken Herrmann's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ken Herrmann has 0.
Where does Ken Herrmann file Form 4?
Ken Herrmann has filed Form 4 at AKTS (Aktis Oncology, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.